Kuvan Safely Aids Growth, Intellect of Youngest Patients Over Long Term, Trial Finds

Kuvan Safely Aids Growth, Intellect of Youngest Patients Over Long Term, Trial Finds

285191

Kuvan Safely Aids Growth, Intellect of Youngest Patients Over Long Term, Trial Finds

Long-term treatment with Kuvan (sapropterin dihydrochloride) helped to control blood levels of phenylalanine, and preserve normal intelligence and growth in infants and children with phenylketonuria (PKU), a Phase 3 trial that followed patients for up to seven years reports. Trial findings were detailed in the study, “Long-term preservation of intellectual functioning in sapropterin-treated infants and young children with phenylketonuria: A seven-year analysis,” published in the journal Molecular Genetics and Metabolism. Marketed by BioMarin, Kuvan is approved…

You must be logged in to read/download the full post.